Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Financings Material +

Charlotte's Web Announces Transaction with BAT: Debenture Conversion and US$10M Equity Investment to Strengthen Balance Sheet

Charlotte’s Web Swaps $65M Debt for BAT’s 40% Stake as Medicare Pilot Kicks Off

By The Northwire Desk — AI Analysis Mar 30, 2026 · 22:59 CWEB · 0.89 CHARLOTTE'S WEB HOLDINGS, INC.
Executive Summary
  • Charlotte’s Web reported Q4 2025 revenue of $13.3M (up 4.7% YoY) and full-year 2025 revenue of $49.9M (up 0.5% YoY), marking the first annual revenue increase since 2021.
  • The company announced a definitive financing transaction with BAT DE Investments involving the conversion of a C$75.3M convertible debenture plus C$14.2M in accrued interest, alongside a US$10M private placement equity investment.
  • The transaction eliminates approximately US$65M in principal debt and halts ~US$12M in future interest accruals. BAT will receive ~110M new shares, representing ~40% of post-transaction outstanding common shares.
  • Q4 2025 net loss widened to $11.5M ($(0.07)/share) from $3.4M in Q4 2024, driven by a $1.3M inventory charge for legacy gummy disposal and continued operating losses. Full-year net loss was $29.7M.
  • Adjusted EBITDA for Q4 was -$4.4M and -$12.9M for FY2025. Cash and cash equivalents fell to $8.0M from $22.6M at year-end 2024.
  • Management highlighted launch partner status in the CMMI Medicare pilot program (effective April 1, 2026) and FDA clearance for DeFloria’s Phase 2 trial of AJA001 for autism spectrum disorder.
  • The transaction requires TSX and shareholder approval, targeted for the AGM/Special Meeting around May 28, 2026.
Material Impact
  • The BAT transaction is fundamentally transformative for the balance sheet, removing the company’s largest liability and stopping a significant interest drain. This eliminates near-term solvency risk tied to the convertible debenture.
  • The US$10M equity injection provides immediate liquidity to fund the CMMI Medicare pilot rollout and sustain operations while the company executes its path to cash flow positivity.
  • Despite the balance sheet repair, the underlying business remains unprofitable. Q4 gross margin compressed to 37.5% due to inventory write-downs, and SG&A remains high at $10.6M. The company continues to burn cash, and the $8.0M cash balance is thin without the BAT proceeds.
  • BAT’s ~40% ownership stake represents substantial dilution for existing shareholders and introduces a dominant strategic partner with board nomination rights. While this aligns long-term interests, it shifts control dynamics and caps near-term upside for minority holders.
  • The CMMI Medicare pilot is a genuine new revenue channel, but it is in early stages with no quantified financial guidance. Reimbursement adoption, patient enrollment, and CMS compliance will dictate actual impact.
CWEB · Price
Company Overview
  • Charlotte’s Web is a U.S.-based botanical wellness company specializing in hemp-derived CBD, minor cannabinoids, and low-dose THC products.
  • Flagship Project: The Brightside™ line of fast-acting, low-dose hemp-derived Delta-9 THC and CBN gummies, utilizing proprietary TiME INFUSION™ technology for 5-15 minute onset. This line targets the high-growth functional wellness and sleep markets.
  • Secondary Initiatives: Expansion into functional mushroom supplements, direct-to-consumer e-commerce optimization, and a strategic pivot toward medical/reimbursement channels via the CMMI Medicare pilot.
  • Clinical Pipeline: 33% equity stake in DeFloria, a joint venture developing AJA001, an FDA-cleared Phase 2 botanical drug candidate for irritability in autism spectrum disorder. Charlotte’s Web holds exclusive commercial manufacturing rights.
Read the original news release →

More from CHARLOTTE'S WEB HOLDINGS, INC.

Jun 26, 2026 · 07:22

Charlotte's Web Provides Update on Diverging Hemp Policies: Federal Momentum Builds as California Restricts Therapeutic Hemp Product Access

Production / Operations May 28, 2026 · 19:34

Charlotte's Web Closes BAT Deal, Eliminating Debt Overhang but Facing Dilution and Revenue Headwinds

Financings May 28, 2026 · 14:23

Charlotte's Web Secures BAT Partnership, But Dilution and Cash Burn Weigh on Sentiment

Financings May 13, 2026 · 07:08

Debt Relief Looms Over Revenue Decline as Liquidity Crunch Precedes Shareholder Vote

Earnings Apr 30, 2026 · 07:00

Charlotte's Web Upgrades to OTCQX as BAT Debt Conversion Stabilizes Balance Sheet

Other Mar 31, 2026 · 07:07

BAT Debt Swap and Medicare Pilot Buy Time as Cash Burn Persists

Earnings